Janux Therapeutics JANX
NASDAQ JANX
$17.09 +0.13 (+0.77%)
As of: Oct 2, 2026 · 9:50 AM EDT

Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)

Updated

Janux Therapeutics (JANX) posted Non-Current Deffered Revenue of $1.08 million for Q2 2026, down 87.6% from the prior quarter.

Analysis

Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends

At the end of FY2022, Janux Therapeutics' Non-Current Deffered Revenue came in at $2.22 million, up 217.3% from FY2021.

  • In prior years, Janux Therapeutics' Non-Current Deffered Revenue was $700,000 in FY2021 (-88.4%) and $6.05 million in FY2020.
  • The Q2 2026 figure stands as the lowest quarterly Non-Current Deffered Revenue since Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Janux Therapeutics 1.06 Bn 1.06 Bn - 1.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.08 Mn
Mar 31, 2026 8.68 Mn
Jun 30, 2023 307,000.00
Mar 31, 2023 1.39 Mn
Dec 31, 2022 2.22 Mn
Sep 30, 2022 3.82 Mn
Jun 30, 2022 5.29 Mn
Dec 31, 2021 700,000.00
Sep 30, 2021 1.84 Mn
Jun 30, 2021 2.82 Mn
Dec 31, 2020 6.05 Mn
API Access

Janux Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=JANX&period=max&api_key=YOUR_API_KEY